Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
almonertinib + pyrotinib
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Almonertinib + pyrotinib is an investigational combination therapy consisting of a third-generation EGFR tyrosine kinase inhibitor (almonertinib) and an irreversible pan-ErbB receptor tyrosine kinase inhibitor (pyrotinib). This regimen is primarily being evaluated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have developed resistance to prior EGFR-TKI therapy and harbor HER2 amplification or mutations. Almonertinib selectively targets EGFR mutations, including T790M, while pyrotinib inhibits HER1, HER2, and HER4, effectively blocking downstream signaling pathways that drive tumor growth. The combination aims to overcome resistance mechanisms mediated by HER2 alterations and is currently being studied in Phase II clinical trials.
- Brand names
- AmeileAiRuiNi
- Other names
- almonertinib + pyrrolitinib
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)ABCB1 (P-glycoprotein)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on almonertinib + pyrotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on almonertinib + pyrotinib.